Park SJ - Search Results

1

TFAP2E methylation status and prognosis of patients with radically resected colorectal cancer.

Park SJ, Kim SM, Hong YS, Lee JL, Kim JE, Kim KP, Hong SM, Jin DH, Kim CW, Yoon YS, Park IJ, Lim SB, Yu CS, Kim JC, Kim TW. Park SJ, et al. Among authors: park ij. Oncology. 2015;88(2):122-32. doi: 10.1159/000362820. Epub 2014 Oct 23. Oncology. 2015. PMID: 25341849

2

Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.

Lee JL, Park I, Park K, Park S, Ahn Y, Ahn JH, Kim TW, Ahn S, Song C, Hong JH, Kim CS, Ahn H. Lee JL, et al. J Cancer Res Clin Oncol. 2012 Apr;138(4):687-93. doi: 10.1007/s00432-012-1148-8. Epub 2012 Jan 12. J Cancer Res Clin Oncol. 2012. PMID: 22237457

3

Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer.

Park SJ, Hong YS, Lee JL, Ryu MH, Chang HM, Kim KP, Ahn YC, Na YS, Jin DH, Yu CS, Kim JC, Kang YK, Kim TW. Park SJ, et al. Oncology. 2012;82(2):83-9. doi: 10.1159/000335959. Epub 2012 Feb 8. Oncology. 2012. PMID: 22327884

4

Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI.

Park K, Lee JL, Park I, Park S, Ahn Y, Ahn JH, Ahn S, Song C, Hong JH, Kim CS, Ahn H. Park K, et al. Med Oncol. 2012 Dec;29(5):3291-7. doi: 10.1007/s12032-012-0227-7. Epub 2012 Mar 30. Med Oncol. 2012. PMID: 22460837

5

Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.

Hong YS, Kim HJ, Park SJ, Kim KP, Lee JL, Park JH, Kim JH, Lim SB, Yu CS, Kim JC, Baek JY, Kim SY, Kim TW. Hong YS, et al. Among authors: park jh, park sj. Cancer Sci. 2013 Apr;104(4):473-80. doi: 10.1111/cas.12098. Epub 2013 Feb 14. Cancer Sci. 2013. PMID: 23298313 Free PMC article.

6

Response evaluation criteria in solid tumors response of the primary lesion in metastatic renal cell carcinomas treated with sunitinib: does the primary lesion have to be regarded as a target lesion?

Park I, Park K, Park S, Ahn Y, Ahn JH, Choi HJ, Jeong IG, Song C, Hong JH, Kim CS, Ahn H, Lee JL. Park I, et al. Clin Genitourin Cancer. 2013 Sep;11(3):276-82. doi: 10.1016/j.clgc.2012.12.005. Epub 2013 Jan 17. Clin Genitourin Cancer. 2013. PMID: 23332873

7

Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.

Park SJ, Lee JL, Park I, Park K, Ahn Y, Ahn JH, Lee DH, Ahn S, Song C, Hong JH, Kim CS, Ahn H. Park SJ, et al. Among authors: park i, park k. Chemotherapy. 2012;58(6):468-74. doi: 10.1159/000346484. Epub 2013 Mar 20. Chemotherapy. 2012. PMID: 23548259

8

The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells.

Park SJ, Hong SW, Moon JH, Jin DH, Kim JS, Lee CK, Kim KP, Hong YS, Choi EK, Lee JS, Lee JL, Kim TW. Park SJ, et al. Am J Med Sci. 2013 Dec;346(6):494-8. doi: 10.1097/MAJ.0b013e318298a185. Am J Med Sci. 2013. PMID: 24051957

9

The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.

Park SJ, Ryu MH, Ryoo BY, Park YS, Sohn BS, Kim HJ, Kim CW, Kim KH, Yu CS, Yook JH, Kim BS, Kang YK. Park SJ, et al. Among authors: park ys. Ann Surg Oncol. 2014 Dec;21(13):4211-7. doi: 10.1245/s10434-014-3866-4. Epub 2014 Jul 1. Ann Surg Oncol. 2014. PMID: 24980089

10

Single-nucleotide polymorphisms in the vascular endothelial growth factor pathway and outcomes of patients treated with first-line cytotoxic chemotherapy combined with bevacizumab for advanced colorectal cancer.

Sohn BS, Park SJ, Kim JE, Kim KP, Hong YS, Suh C, Kim YS, Kim SY, Im SA, Kim SY, Kim JH, Ahn JB, Park YS, Kim TW. Sohn BS, et al. Among authors: park ys, park sj. Oncology. 2014;87(5):280-92. doi: 10.1159/000365593. Epub 2014 Aug 15. Oncology. 2014. PMID: 25139485

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,448 results

Search Page

Filters